MXPA03000547A - Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares. - Google Patents

Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.

Info

Publication number
MXPA03000547A
MXPA03000547A MXPA03000547A MXPA03000547A MXPA03000547A MX PA03000547 A MXPA03000547 A MX PA03000547A MX PA03000547 A MXPA03000547 A MX PA03000547A MX PA03000547 A MXPA03000547 A MX PA03000547A MX PA03000547 A MXPA03000547 A MX PA03000547A
Authority
MX
Mexico
Prior art keywords
derivatives
valproenic
mania
treatment
bipolar disorder
Prior art date
Application number
MXPA03000547A
Other languages
English (en)
Inventor
Mitchell Shirvan
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MXPA03000547A publication Critical patent/MXPA03000547A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un metodo para el tratamiento de mania en el trastorno bipolar, que utiliza derivados de amidas de acido valproico y de acido 2-valproenico, que tienen las siguientes estructuras: en donde R1, R2 y R3 son independientemente iguales o diferentes y son hidrogeno, un grupo C1-C6 alquilo, un grupo aralquilo, o un grupo arilo, y n es un entero que es mayor que o igual a 0 y menor que o igual a 3, o un compuesto que contiene una porcion valproica o 2-valproenica, asi como tambien composiciones farmaceuticas que comprenden estos derivados o compuestos. (ver formulas).
MXPA03000547A 2000-07-21 2001-07-20 Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares. MXPA03000547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22010200P 2000-07-21 2000-07-21
PCT/US2001/023116 WO2002007677A2 (en) 2000-07-21 2001-07-20 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder

Publications (1)

Publication Number Publication Date
MXPA03000547A true MXPA03000547A (es) 2004-04-05

Family

ID=22822065

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000547A MXPA03000547A (es) 2000-07-21 2001-07-20 Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.

Country Status (16)

Country Link
US (2) US6555585B2 (es)
EP (1) EP1303289A4 (es)
JP (1) JP2004520263A (es)
KR (1) KR100843703B1 (es)
CN (1) CN1251758C (es)
AU (1) AU2001280699A1 (es)
CA (1) CA2416821A1 (es)
CZ (1) CZ2004266A3 (es)
HU (1) HUP0600526A2 (es)
IL (1) IL153942A0 (es)
MX (1) MXPA03000547A (es)
NO (1) NO20030295L (es)
NZ (1) NZ523917A (es)
PL (1) PL365588A1 (es)
WO (1) WO2002007677A2 (es)
ZA (1) ZA200300641B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153942A0 (en) * 2000-07-21 2003-07-31 Teva Pharma Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
US20060223888A1 (en) * 2002-12-16 2006-10-05 Abbott Frank S Valproic acid analogues and pharmaceutical composition thereof
US20040175423A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds
US20040176463A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Immediate release formulation of n-(2-propylpentanoyl)glycinamide
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
IL156203A0 (en) * 2003-05-29 2003-12-23 Yissum Res Dev Co Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2006012603A2 (en) * 2004-07-22 2006-02-02 Nps Pharmaceuticals, Inc. Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
WO2007028030A2 (en) * 2005-09-02 2007-03-08 Picobella, Llc Oncogenic regulatory rnas for diagnostics and therapeutics
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
US10125365B2 (en) 2014-02-05 2018-11-13 Yeda Research And Development Co. Ltd. Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
AU2017374458B2 (en) * 2016-12-14 2023-03-02 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU988188A3 (ru) 1973-12-14 1983-01-07 Эсакмадьяросаги Ведьимювек (Инопредприятие) Способ получени N,N-дизамещенных амидов карбоновых кислот
DE3050800C2 (es) 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be
US4301176A (en) * 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
FR2489319A1 (fr) * 1980-08-27 1982-03-05 Clin Midy Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant
BE885303A (fr) 1980-09-19 1981-03-19 Continental Pharma Glycinamides
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
DK373383A (da) 1982-08-20 1984-02-21 Midit Fremgangsmaade til fremstilling af omega-aminosyrederivater
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3785667T2 (de) 1986-09-17 1994-07-21 Clintec Nutrition Co Zusatznahrung bzw. therapie für personen mit risiko oder in behandlung für arteriosklerotische vaskuläre, kardiovaskuläre und/oder thrombotische erkrankungen.
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
IL126203A (en) 1996-03-25 2002-12-01 Lilly Co Eli A synergistic painkiller that contains olenzapine and another painkiller
IL121268A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
PL345364A1 (en) 1998-06-22 2001-12-17 American Biogenetic Sciences The use of valproic acid analog for the treatment and prevention of migraine and affective illness
IL153942A0 (en) * 2000-07-21 2003-07-31 Teva Pharma Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder

Also Published As

Publication number Publication date
JP2004520263A (ja) 2004-07-08
EP1303289A4 (en) 2009-08-05
WO2002007677A2 (en) 2002-01-31
WO2002007677A3 (en) 2002-05-30
EP1303289A2 (en) 2003-04-23
CN1251758C (zh) 2006-04-19
US6555585B2 (en) 2003-04-29
NO20030295D0 (no) 2003-01-20
KR100843703B1 (ko) 2008-07-04
US20020103237A1 (en) 2002-08-01
CZ2004266A3 (cs) 2005-02-16
US20030212142A1 (en) 2003-11-13
PL365588A1 (en) 2005-01-10
ZA200300641B (en) 2004-01-26
AU2001280699A1 (en) 2002-02-05
NO20030295L (no) 2003-01-20
KR20030036610A (ko) 2003-05-09
IL153942A0 (en) 2003-07-31
NZ523917A (en) 2004-11-26
CN1446097A (zh) 2003-10-01
CA2416821A1 (en) 2002-01-31
HUP0600526A2 (en) 2006-11-28

Similar Documents

Publication Publication Date Title
GR3030183T3 (en) Derivatives of valproic and 2-valproenoic acid amides and use as anticonvulsants.
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
MXPA03007249A (es) Compuestos triazolo como inhibidores de mmp.
DE69512797D1 (en) Prostaglandin-synthase hemmer
ATE201019T1 (de) 9-deoxotaxan verbindungen
UA61124C2 (en) New pentasaccharides, a method for preparing thereof and pharmaceutical compositions containing them
AU558261B2 (en) Dialkylaminoalkyoxybenzylalcohol derivatives
MX9708735A (es) Benzotiazoles y benzoxazoles, composiciones farmaceuticas que contienen estos compuestos y su uso y proceso para prepararlos.
AP1518A (en) Novel octahydro-6, 10-dioxo-6h-pyridazino/1,2-a/ /1,2/diazepin-1-carboxylic acid derivatives, preparation method and use for preparing therapeutically active compounds.
DE69429753D1 (de) Anitbiotisch wirksame Cephalosporine und Verfahren zu ihrer Herstellung
HUP0100564A2 (hu) Matrix metalloproteináz inhibitorok és ilyeneket tartalmazó gyógyszerkészítmények
IL115085A0 (en) Bicyclic carboxamide derivatives their preparation and pharmaceutical compositions containing them
IL149153A0 (en) Oligobenzimidazole derivatives and their use as dna transfection agents
NZ509327A (en) Alpha-amino acid phenyl ester derivatives for use in general anaesthesia
CA2238710A1 (en) New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds
MXPA01005363A (es) 4'-substituido-4',5'-dihidropsoralen y usos terapeuticos del mismo.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights